#16
|
||||
|
||||
Ññûëêà íà ðàçìåùåííûå â äðóãîì ðàçäåëå ðåêîìåíäàöèè è èõ íåîôèöèàëüíûé ïåðåâîä:
Àíòèòðîìáîòè÷åñêàÿ òåðàïèÿ (ïðèëîæåíèå) - ãàéä ICSI Antithrombotic Therapy Supplement
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#17
|
||||
|
||||
Âûøëî îáíîâëåíèå ðåêîìåíäàöèé Àìåðèêàíñêîãî îáùåñòâà ñîñóäèñòûõ õèðóðãîâ è Àìåðèêàíñêîãî âåíîçíîãî ôîðóìà ïî ëå÷åíèþ çàáîëåâàíèé âåí (30.08.2011).
Ôóëë òåêñò (àíãë., pdf): [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Áåçóñëîâíî, ýòî îòëè÷íî ïðîðàáîòàííûå äåòàëüíûå ðåêîìåíäàöèè, êîòîðûå ñòîèò ó÷èòûâàòü â ñâîåé ðàáîòå.
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#18
|
||||
|
||||
Ãàéä ïî ïðîôèëàêòèêå ÒÃÂ îò American College of Physicians
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Îïóáëèêîâàí â Annals of Internal Medicine November 1, 2011 vol. 155 no. 9 625-632 |
#19
|
||||
|
||||
Âðåìÿ èäåò, è ðåêîìåíäàöèè ACCP (American College of Chest Physicians) ïî àíòèòðîìáîòè÷åñêîé è òðîìáîëèòè÷åñêîé òåðàïèè â 9 âåðñèè (2012 ãîä) ñòàëè îáùåäîñòóïíû:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#20
|
||||
|
||||
Êñàðåëòî äëÿ ÒÃÂ è ÒÝËÀ
Ïåðåïîñò ïîëó÷åííîãî ìíîé ñîîáùåíèÿ:
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#21
|
||||
|
||||
Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism
ASH Education Book December 6, 2013: 471-477 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#22
|
||||
|
||||
Ïðàäàêñà (Äàáèãàòðàí) è òðîìáîçû ãëóáîêèõ âåí, ÒÝËÀ
Ïðèøëî îïîâåùåíèå î ðåãèñòðàöèè äëÿ Ïðàäàêñû ïîêàçàíèé ê ëå÷åíèþ è ïðîôèëàêòèêå Òàè/èëè ÒÝËÀ. Ñ îïîâåùåíèåì è ñ èçìåíåííîé èíñòðóêöèåé ìîæíî ïîçíàêîìèòüñÿ çäåñü: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Íà ñàéòå Ãîñóäàðñòâåííîãî ðååñòðà ëåêàðñòâåííûõ ñðåäñòâ ïîêà íîâîé èíñòðóêöèè íå âèæó, íî, ñêîðåå âñåãî, ýòî âîïðîñ íåáîëüøîãî âðåìåíè.
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
|
#23
|
||||
|
||||
Èíòåðåñíûå íåäàâíèå êåéñû-ïóáëèêàöèè î ïðèìåíåíèè ìåñòíûõ áåòà-áëîêåðîâ â ëå÷åíèè ñîñóä. ÿçâ:
Topical timolol for a refractory wound. Tang JC, Dosal J, Kirsner RS. Dermatol Surg. 2012 Jan;38(1):135-8. Successful treatment of a chronic venous leg ulcer using a topical beta-blocker. Lev-Tov H, Dahle S, Moss J, Isseroff RR. J Am Acad Dermatol. 2013 Oct;69(4):e204-5. Topical timolol for recalcitrant wounds. Braun LR, Lamel SA, Richmond NA, Kirsner RS. JAMA Dermatol. 2013 Dec;149(12):1400-2. Topical timolol for a chronic ulcer--a case with its own control. Manahan MN, Peters P, Scuderi S, Surjana D, Beardmore GL. Med J Aust. 2014 Jan 20;200(1):49-50. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ÐÊÈ ïîõîæå â áëèæ. âðåìÿ íå ïðåäâèäèòñÿ - èç ïîñëåäíåé ïóáëèêàöèè: "Timolol has the potential to be an inexpensive, non-invasive and non-labour intensive means to assist wound healing for chronic ulcers. A Phase II trial, looking at the use of topical timolol in ulcers, was halted due to lack of funding..."
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#24
|
||||
|
||||
Ïðèåì ñòàòèíîâ ñíèæàåò ðèñê ïîâòîðà ÒÃÂ íà ïîïóëÿöèîííîì óðîâíå:
Using the Danish National Patient Registry, we identified first-time and recurrent VTEs between 1 July 2004 and 31 December 2012 (n=27,862). VTE diagnoses were validated by medical record review of a subsample of patients. We ascertained nationwide prescription data and categorized statin use as current (further divided into new and long-term use), former, and no use. We identified statin use at baseline (mimicking an intention-to-treat analysis) and in time-varying manner during follow-up (mimicking per-protocol analysis) and computed hazard ratios (HRs) for recurrent VTE using Cox regression. In a supplementary nested case-control study, we identified statin use at time of VTE recurrence and computed odds ratios as unbiased estimates of the incidence rate ratios (IRRs) using conditional logistic regression. We adjusted for age, sex, year of diagnosis, provoking factors, comorbidities, and co-medications, including time-varying use of aspirin and anticoagulant drugs. RESULTS: The adjusted HR comparing current use with no use was 0.72 (95% confidence interval [CI] 0.59-0.88) for recurrent VTE, with a stronger effect of high (0.40, 95% CI 0.21-0.78) vs. low potency statins (0.77, 95% CI 0.63-0.94). Consistently, the recurrence rate was reduced in both the time-varying analysis (HR=0.64, 95% CI 0.54-0.77) and nested case-control analysis (IRR=0.55, 95% CI 0.45-0.67). The effect was largest for recurrent deep venous thrombosis. J Thromb Haemost. 2014 May 12. Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#25
|
||||
|
||||
Blood. 2014 May 30.
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. Palareti G1, et al. The optimal duration of anticoagulation in patients with venous thromboembolism (VTE) is uncertain. We investigated whether persistently negative D-dimers in patients with vein recanalization or stable thrombotic burden can identify subjects at low recurrence risk. Outpatients with a first VTE (unprovoked or associated with weak risk factors) were eligible after at least 3 months (12 in those with residual thrombosis) of anticoagulation. They received serial D-dimer measurements using commercial assays with predefined age/sex-specific cut-offs and were followed up for up to two years. Out of 1010 patients, anticoagulation was stopped in 528 (52.3%) with persistently negative D-dimer, who subsequently experienced 25 recurrences (3.0% pt-y; 95% CI 2.0 - 4.4%). Of the remaining 482 patients, 373 resumed anticoagulation and 109 refused it. Recurrent VTE developed in 15 patients (8.8% pt-y; 95% CI 5.0-14.1) of the latter group and in 4 of the former (0.7% pt-y; 95% CI 0.2-1.7; HR = 2.92; 95% CI 1.87 - 9.72; P = 0.0006). Major bleedings occurred in 14 patients (2.3% pt-y; 95% CI 1.3-3.9) who resumed anticoagulation. Serial D-dimer measurement is suitable in clinical practice for the identification of VTE patients in whom anticoagulation can be safely discontinued.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#26
|
||||
|
||||
Êàíàäñêèå ðåêîìåíäàöèè ïî òðîìáîïðîôèëàêòèêå ïðè áåðåìåííîñòè îò 2014 ã.:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#27
|
||||
|
||||
Ïðèìåíåíèå áåòà-áëîêàòîðîâ ó äåòåé ðàñøèðÿåòñÿ: îïûò èõ ïðèìåíåíèÿ ïðè ïèîãåííûõ ãðàíóëîìàõ îïèñûâàåòñÿ â íåäàâíåé ïóáëèêàöèè
Pediatr Dermatol. 2014 Mar-Apr;31(2):203-7. Treatment of pediatric pyogenic granulomas using β-adrenergic receptor antagonists. Wine Lee L, Goff KL, Lam JM, Low DW, Yan AC, Castelo-Soccio L. Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania; Section of Pediatric Dermatology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Propranolol and timolol are nonselective ß-adrenergic antagonists that induce peripheral vasoconstriction and affect angiogenic cytokines. Oral and topical ß-blocker therapy has become the de facto first-line treatment for complicated infantile hemangiomas because of its superior efficacy and tolerability. Pyogenic granulomas or lobular capillary hemangiomas are common acquired vascular tumors accounting for 0.5% of all skin nodules in children. Although they are benign vascular proliferations, treatment is often sought because of recurrent episodes of bleeding and for cosmetic considerations. Numerous treatment options are available, but recurrence rates are high. Noninvasive methods of treatment are being sought, particularly for young children. Herein we report a series of seven cases of cutaneous and mucosal pyogenic granulomas treated successfully using oral or topical ß-blockers.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#28
|
||||
|
||||
Êîíñåíñóñíûé äîêóìåíò ïî ïðîôèëàêòèêå ÂÒÝÎ îò 2013 ã.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#29
|
||||
|
||||
Ïðèëîæåíèå äëÿ èçìåðåíèÿ ïëîùàäè òðîôè÷åñêèõ ÿçâ, ðàí, îæîãîâ è ëþáûõ ôèãóð íåïðàâèëüíîé ôîðìû: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#30
|
||||
|
||||
Family history of venous thromboembolism as a risk factor and genetic research tool.
ïîëíûé òåêñò äîñòóïåí ïî ññûëêå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |